SLAMF6 Discovery Advances Cancer Immunotherapy; Replimune Reports Financial Status
Scientists have identified SLAMF6 as a key suppressor of T cell immunity against cancer and developed monoclonal antibodies that neutralize it in mice, published in Nature. Biotechnology company Replimune Group has reported its 2026 financial position, with a market value of approximately $234.5 million and ongoing clinical trials.
A study published in Nature has identified SLAMF6 as a key molecule that suppresses T cell immunity against cancer, and researchers have developed monoclonal antibodies that neutralize it in mice, offering a potential new immunotherapy for patients who do not respond to existing treatments. The discovery, led by researchers at the Montreal Clinical Research Institute, demonstrates that SLAMF6 acts as an internal brake on T cells, independent of tumor cells, and the newly developed antibodies significantly enhance T cell activation and anti-tumor responses.
The research shows that current immunotherapies, such as PD1 or PDL1 inhibitors, release brakes imposed by tumors, but a large number of patients either do not respond or eventually stop responding. The new monoclonal antibodies prevent SLAMF6 from interacting with itself, leading to more activation of human T cells, higher numbers of resilient immune cells, fewer exhausted T-cells, and strong anti-tumour responses in mice. These antibodies outperform all currently available tools targeting SLAMF6 and could be used alone or in combination with other immune-stimulating therapies. The next step is testing these antibodies in early-phase clinical trials to evaluate safety and efficacy in people with solid tumours or blood cancers.
Meanwhile, Replimune Group, Inc., a biotechnology company focused on viral-based immunotherapies for cancer, has reported its financial position in its 2026 annual report. The company's Form 10-K for the fiscal year ended March 31, 2026, shows an aggregate market value of common stock held by non-affiliates at approximately $234.5 million as of September 30, 2025, with 83,945,161 shares outstanding as of June 25, 2026. Replimune is classified as a non-accelerated filer and smaller reporting company.
Replimune operates in the highly competitive oncology market, facing competition from larger pharmaceutical and biotech companies. The company is focusing on qualifying and maintaining its in-house manufacturing facility, while supply chain risks, including single-source suppliers for key materials, may impact operations. Intellectual property protection is vital for its competitive advantage.
The annual report contains forward-looking statements regarding clinical trial advancement, cash runway, commercial strategy, and regulatory approvals. Key risks include the ability to operate manufacturing facilities, maintain supply chains, estimate expenses, implement strategic plans, achieve market acceptance, and establish collaborations. Replimune expects to file a definitive proxy statement within 120 days of the fiscal year end, and management has highlighted ongoing clinical trials and regulatory submissions as near-term catalysts.